

Abiomed, Inc. and Subsidiaries
Consolidated Balance Sheets
(Unaudited)
(in thousands, except share data)

September 30, 2017 March 31, 2017

ASSETS

Current assets:

| | | |
|---|------------|------------|
| Cash and cash equivalents | \$ 44,536 | \$ 39,040 |
| Short-term marketable securities | 218,661 | 190,908 |
| Accounts receivable, net | 57,327 | 54,055 |
| Inventories | 40,632 | 34,931 |
| Prepaid expenses and other current assets | 9,014 | 8,024 |
| Total current assets | 370,170 | 326,958 |
| Long-term marketable securities | 55,954 | 47,143 |
| Property and equipment, net | 97,697 | 87,777 |
| Goodwill | 34,332 | 31,045 |
| In-process research and development | 16,016 | 14,482 |
| Long-term deferred tax assets, net | 106,798 | 34,723 |
| Other assets | 13,686 | 8,286 |
| Total assets | \$ 694,653 | \$ 550,414 |

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

| | | |
|------------------|-----------|-----------|
| Accounts payable | \$ 16,667 | \$ 20,620 |
| Accrued expenses | 35,256 | 37,703 |

| | | |
|---|------------|------------|
| Deferred revenue | 10,584 | 10,495 |
| Current portion of capital lease obligation | 851 | 799 |
| Total current liabilities | 63,358 | 69,617 |
| Other long-term liabilities | 598 | 3,251 |
| Contingent consideration | 9,835 | 9,153 |
| Long-term deferred tax liabilities | 866 | 783 |
| Capital lease obligation, net of current portion | 15,110 | 15,539 |
| Total liabilities | 89,767 | 98,343 |
| Commitments and contingencies | | |
| Stockholders' equity: | | |
| Class B Preferred Stock, \$.01 par value | — | — |
| Authorized - 1,000,000 shares; Issued and outstanding - none | | |
| Common stock, \$.01 par value | 442 | 437 |
| Authorized - 100,000,000 shares; Issued - 45,921,029 shares at September 30, 2017 and 45,249,281 shares at March 31, 2017 | | |
| Outstanding - 44,200,784 shares at September 30, 2017 and 43,673,286 shares at March 31, 2017 | | |
| Additional paid in capital | 592,081 | 565,962 |
| Retained earnings (accumulated deficit) | 90,164 | (46,959) |
| Treasury stock at cost - 1,720,245 shares at September 30, 2017 and 1,575,995 shares at March 31, 2017 | (65,999) | (46,763) |
| Accumulated other comprehensive loss | (11,802) | (20,606) |
| Total stockholders' equity | 604,886 | 452,071 |
| Total liabilities and stockholders' equity | \$ 694,653 | \$ 550,414 |